



ACS NLCRT Lung Cancer Biomarker Testing ECHO Year 3

Post Session 5: Recap & Resources

This document compiles some of the key resources mentioned during the **Session 5: Navigating Insurance Complexities**. To review all publications, articles, or commentaries mentioned, we recommend reviewing the presentation recording and PowerPoint presentation.

All slides and recordings can be found [here](#).

HIGHLIGHTS OF SESSION RESOURCES

- American Cancer Society Cancer Action Network (ACS CAN) Survivor Views Survey Results, 2023 [Link](#)
- ACS CAN Survivor Views Survey Results (detailing out-of-pocket costs), 2020 [Link](#)
- Improving Access to Biomarker Testing (ACS CAN & Lungevity Report), 2020 [Link](#)
- Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumors [Link](#)
- Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer [Link](#)
- American Cancer Society Cancer Action Network Access to Biomarker Testing [Link](#)
- Health Equity in Biomarker Testing and Targeted Therapy Factsheet (ACSCAN) [Link](#)
- State Legislation Requiring Coverage of Biomarker Testing Gains Momentum [Link](#)
- The Landscape of Biomarker Testing Coverage in the US (ACSCAN White Paper) [Link](#)
- Payer Coverage Policies of Tumor Biomarker and Pharmacogenomic Testing (ACS CAN Report), 2023 [Link](#)
- Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study [Link](#)

TOOLS/RESOURCE OF POTENTIAL INTEREST

- **GO2 For Lung Cancer Patient Education Materials:** Biomarker Testing [Link](#) ; Targeted Therapy [Link](#); Immunotherapy [Link](#)
- Free CME/CNE - Interpreting cancer biomarker testing - When is additional testing needed? (jax.org) [Link](#)